ACME Research Solutions is an ISO and GMP-certified pharmaceutical research organisation headquartered in Baghpat, India, operating across Asia, Europe, and beyond. With 350+ studies completed and 270+ international projects delivered, the company specialises in in vitro assays, formulation development, drug delivery systems, and analytical chemistry. Its mission is sharper than most: to dismantle the gatekeeping that has long defined global pharmaceutical research and replace it with a model where access, affordability, and rigour coexist.

Built on scientific integrity, accessibility, and mentorship-first leadership, ACME Research Solutions has become the research backbone for universities, independent scientists, and pharmaceutical companies across continents.

The Leader and His Conviction

Dr. Akhilesh Vats, Founder and Director, built ACME Research Solutions from the ground up, without institutional backing, government grants, or legacy advantage. His conviction was singular: quality science should never be limited by privilege.

ACME Research Solutions was created to address a fracture the industry had long ignored. Talented researchers in developing regions had no access to credible laboratory infrastructure, while global research services remained priced for the privileged few. What began as an intervention evolved into an institution where mission led, and commerce followed conviction.

At just 35, Dr. Vats holds an Honorary Lifetime Fellowship (F. GAPTR), edits the PEXACY International Journal of Pharmaceutical Science, and is listed as a Qualified Scientist for Regeneron ISEF 2026, USA. PEXACY, under his editorship, has been cited by Nature, Wiley, Frontiers, and Taylor & Francis, demonstrating how independent research ecosystems can shape global scientific discourse from outside the legacy system.

Research Capabilities and Value Proposition

ACME Research Solutions delivers full-spectrum pharmaceutical research, including in vitro assays, permeation studies, nanoemulsion formulation, analytical chemistry, and drug delivery systems. Every study ships with complete documentation, raw data traceability, and statistical rigour as standard, not as a premium add-on.

Price is incidental. Philosophy is the product. Publication-readiness is the baseline at ACME Research Solutions, and clients receive structured, peer-review-ready scientific dossiers, with outputs cited in internationally indexed journals. With 150+ M.Pharm scholars mentored and 270+ global projects completed, credibility here is built on citations, not claims.

Credibility, Mentorship, and Measurable Impact

In a field where institutional legacy still outranks merit, Dr. Vats built trust the harder way: through verifiable outcomes.

He launched PEXACY International Journal with ISSN accreditation and OpenAIRE indexing, drawing global citations within months of inception. He has mentored researchers to national and international recognition, including a Regeneron ISEF 2026 finalist from the Philippines. The takeaway is simple: pedigree is no longer a prerequisite for world-class science.

Mentorship is not adjacent to ACME Research Solutions’ mission. It is the mission. Over 17+ PhD scholars have completed their degrees, and 200+ researchers have published in indexed, peer-reviewed journals under his guidance.

From a Regeneron ISEF 2026 qualifier in Southeast Asia to a roster of national and regional science champions across the Philippines and India, the outcomes form a replicable blueprint for research democratisation. Dr. Vats puts it plainly: "Your ceiling is someone else's floor. Raise it."

Competitive Edge, Innovation, and Future Readiness

ACME Research Solutions competes on three fronts that global pharma rarely combines: depth, speed, and affordability. The organisation delivers PhD-level research output with full data validation at roughly half the global market rate, with turnaround times that outpace international competitors.

It does not function as a vendor. It functions as an institution where access, standards, and impact are non-negotiable.

ACME Research Solutions has also engineered proprietary research automation systems in-house, including IC₅₀ analysis, wound healing quantification, drug release modelling, and patent drawing conversion to UK standards. While much of the industry is still evaluating AI's role in pharmaceutical research, ACME Research Solutions has already operationalised it.

The roadmap ahead is clear: scale ACME Research Solutions into a global scientific institution, advance a pipeline of 100+ design patents, and expand PEXACY into the publishing platform of choice for underserved researchers worldwide.

Leadership Mantra

In Dr. Vats’ words:

“The future belongs to distributed science. Automation, open-access publishing, and cross-border mentorship are dismantling the gatekeeping structures that defined the last century. ACME Research Solutions does not participate in this frontier. It leads it.

Science should not have a postcode. Talent does not. Curiosity does not. The only barrier has ever been access, and that is the variable this work was built to eliminate.”